The combination of the HSP90 inhibitor PU-H71 and the MCL1 inhibitor S63845 may be a candidate treatment for FLT3-mutated AML with moderate CD34 positivity, while the combination of HSP90 inhibitor PU-H71 and BCL2 inhibitor venetoclax may be more effective in the treatment of primitive AML with high CD117 and low CD11b positivity [8]. Here, CD34 is linked to acute myeloid leukemia.